POOLBEG PHARMA PLC - POLBF STOCK NEWS

Poolbeg Pharma has announced a significant change in its major holdings following an acquisition of voting rights. Michael Kelly has now increased his voting rights to 5.2%, crossing the previous threshold of 4.8%. The change was officially recorded on July 4, 2024, and the company was notified by July 9, 2024. The total number of voting rights now held by Kelly stands at 26,039,455. This notification complies with the regulatory requirements and has been filed with the Financial Conduct Authority (FCA).

Poolbeg Pharma, a biopharmaceutical company developing innovative medicines for diseases with high unmet needs, has announced a change in its registered address. The new address is 40 Bank Street, Floor 24, London, E14 5NR, United Kingdom. This strategic move aligns with the company's ongoing growth and operational adjustments.

Poolbeg Pharma, a UK-based biopharmaceutical company, announced that all resolutions presented at their Annual General Meeting on June 17, 2024, were approved by shareholders. The company, traded under AIM:POLB and OTCQB:POLBF, focuses on developing and commercializing innovative medicines for diseases with high unmet medical needs. This successful AGM marks a positive step for Poolbeg as they continue their mission to address critical health challenges.

Poolbeg Pharma PLC, a biopharmaceutical company, releases its Annual Report and AGM Notice for the period ending December 31, 2023. The Annual General Meeting is scheduled for June 13, 2024, in London. Shareholders can access the reports and proxy form on the company's website.

Poolbeg Pharma PLC has announced the significant granting of the POLB 001 patent in the USA, reinforcing its intellectual property portfolio. The patent covers drugs for treating hypercytokinaemia and preventing cytokine storms in patients post-immune response. This strengthens the company's IP portfolio and enhances the value of POLB 001 for potential partners. Poolbeg Pharma is actively building a global IP portfolio, with additional patents for severe influenza and cytokine release syndrome after cancer immunotherapy.

Poolbeg Pharma PLC has announced its results for the year ended 31 December 2023, highlighting significant pipeline advancements, expansion into cancer immunotherapy-induced CRS, and key management hires. Financially, the company reported a cash balance of £12.2 million and appointed industry veteran Professor Brendan Buckley as a Non-Executive Director. Operationally, positive results were seen from the POLB 001 LPS human challenge trial, and strategic expansions and collaborations were made to strengthen the company's portfolio. Post-period end, positive in vivo data confirmed the efficacy of POLB 001 in reducing cancer immunotherapy-induced CRS, positioning the company well for future success.

Poolbeg Pharma PLC announced the appointment of Shore Capital Stockbrokers as its Joint Broker, with Cavendish Capital Markets remaining as the Nominated Adviser and Joint Broker alongside J&E Davy. The company focuses on developing and commercializing innovative medicines for diseases with high unmet medical needs.

Poolbeg Pharma PLC has announced an option agreement to acquire an orphan drug candidate for Behçet's Disease. The exclusive 12-month option agreement with Silk Road Therapeutics Inc is for a novel topical muco-adherent formulation of Pentoxifylline (tPTX) to treat oral ulcers in patients with Behçet's Disease. The drug has completed a successful Phase 2 trial, demonstrating superiority over the current standard of care. It has secured Orphan Drug Designation and Fast Track Designation from the FDA, positioning it for a potential 505(b)(2) approval pathway in the U.S.

Poolbeg Pharma PLC has announced a TR-1 notification of major holdings, with Michael Kelly holding 4.8% of voting rights attached to shares, as of 15th March 2024. The press release provides details on the notification, including the reason, persons subject to the notification obligation, and the resulting situation on the date of the threshold being crossed or reached. This indicates a significant development in the company's shareholder structure, potentially influencing decision-making and corporate governance.